NX1 — Nexalis Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$4.31m
- AU$4.61m
- AU$0.99m
Annual balance sheet for Nexalis Therapeutics, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.8 | 2.13 | 0.716 | 0.195 | 0.437 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.019 | 0.032 | 0.802 | 0.447 | 0.915 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 2.91 | 2.24 | 1.58 | 0.712 | 1.43 |
| Net Property, Plant And Equipment | 0.01 | 0 | — | — | — |
| Net Intangible Assets | |||||
| Total Assets | 2.93 | 2.26 | 1.58 | 0.712 | 1.43 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.253 | 0.355 | 0.911 | 0.776 | 2.07 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.253 | 0.355 | 0.911 | 0.445 | 2.05 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2.68 | 1.9 | 0.665 | 0.267 | -0.619 |
| Total Liabilities & Shareholders' Equity | 2.93 | 2.26 | 1.58 | 0.712 | 1.43 |
| Total Common Shares Outstanding |